mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

International Journal of Cancer

Volumn 108, Issue 5, 2004, Pages 704-711

  Greiner, Jochen ^a   Ringhoffer, Mark ^a   Taniguchi, Masanori ^b   Li, Li ^a   Schmitt, Anita ^a   Shiku, Hiroshi ^b   Döhner, Hartmut ^a   Schmitt, Michael ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MIE UNIVERSITY   (Japan)

Author keywords

AML; Expression profiling; Immunotherapies; Leukemia associated antigens; SEREX

Indexed keywords

ANTIGEN; ANTIGEN BAGE; ANTIGEN G250; ANTIGEN HTERT; ANTIGEN MPP11; ANTIGEN PRAME; ANTIGEN RHAMM; ANTIGEN WT1; LEUKEMIA ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLAST CELL; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE DISEASE; ADULT; AGED; ANTIGENS, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0347285399     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11623     Document Type: Article

References (51)

1. Stockerl-Goldstein KG, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell transplantation. 2nd ed. Oxford: Blackwell Science, 1999. p 823-34.
2. Foa R, Fierro MT, Tosti S. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leukemia Lymphoma 1990;1:113.
3. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
4. Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen C, Bongaerts R, Lurvink E, van der Hoorn M, Kluck P, Landegent JE, Kluin-Nelemans HC, Fibbe WE, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94:1201-8.
5. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermüller J, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
6. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:975-80.
7. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:416-7.
8. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, van der Bruggen P. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995;2:167-75.
9. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
10. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
11. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
12. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-8.
13. Türeci O, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, Tsang S, Seitz G, Old LJ, Pfreundschuh M. Expression of SSX genes in human tumors. Int J Cancer 1998;77:19-23.
14. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
15. Van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
16. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90:1217-25.
17. Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997;90:4230-2.
18. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
19. Hosen N, Sonoda Y, Oji Y, Kimura T, Minamiguchi H, Tamaki H, Kawakami M, Asada M, Kanato K, Motomura M, Murakami M, Fujioka T, et al. Very low frequencies of human normal CD34+ haematopoetic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 2002;116:409-20.
20. Greiner J, Ringhoffer M, Simikopinko O, Szmaragowska A, Maurer U, Bergmann L, Schmitt M. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia (AML). Exp J Hematol 2000;28:1413-22.
21. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett J. Targeted T-cell therapy for human leukaemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996;88:2450-7.
22. Molldrem J, Lee PP, Wang C, Champlin RE, Davis MM. A PRI-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myeloid leukemia. Cancer Res 1999;59:2675-81.
23. Dengler R, Münstermann U, Al-Barran S, Hausner I, Faderl S, Nerl C, Emmerich B. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) I normal and leukaemic myeloid cells. Br J Haematol 1995:89:250-7.
24. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, Schmitt M. RHAMM is a new immunogenic tumor-associated antigen overexpressed in acute and chronic myeloid leukemia. Exp J Hematol 2002;30:1029-35.
25. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Döhner H, Schmitt M. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CML). Int J Cancer 2003;106:224-31.
26. Wu C, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, Alyea EP, Soiffer RJ, Dranoff G, Ritz J. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000;106:705-14.
27. Chomezynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-7.
28. Greiner J, Ringhoffer M, Szmaragowska A, Hübsch S, Döhner H, Schmitt M. Quantitative measurement of the mRNA expression of the tumor-associated antigen PRAME by real-time RT-PCR using the LightCycler and SYBR Green I Technology. In: Dietmaier W, Wittwer C, Sivasubramanian N, eds. Rapid cycle real time PCR-methods and applications, genetics and oncology. Heidelberg, Germany: Springer, 2002. p 177-86.
29. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. Her-2/neu derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998;58:732-6.
30. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1998;244:707-12.
31. Neumann E, Engelsberg A, Decker J, Storkel S, Jäger E, Huber C, Seliger B. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies. Cancer Res 1998;58:4090-5.
32. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Türeci O, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
33. Türeci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci USA 1998;95:5211-6.
34. Eichmüller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous lymphoma-associated antigens. Proc Natl Acad Sci USA 2001;98:629-34.
35. Rearden A. A new lim protein containing an autoepitope homologous to "senescent cell antigen." Biochem Biophys Res Commun 1994;201:1124-31.
36. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongereel V, Gure AO, Jäger D, Jäger E, Knuth A, Chen YT, Old LJ. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999;83:456-64.
37. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-7.
38. Adams SP, Sahota S, Mijovic A, Czepulkowski B, Padua RA, Mufti GJ, Guinn BA. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002;16:2238-42.
39. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59:5554-9.
40. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-95.
41. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999;10:673-9.
42. Shoji W, Inoue T, Yamamoto T, Obinata M. MIDAI, a protein associated with Id, regulates cell growth. J Biol Chem 1995;270:24818-25.
43. Inoue T, Shoji W, Obinata M. MIDAI, an Id-associating protein, has two distinct DNA binding activities that are converted by the association with Id1: a novel funtion of Id protein. Biochem Biophys Res Commun 1999;266:147-51.
44. Resto VA, Caballero OL, Buta MR, Westra WH, Wu L, Westendorf JM, Jen L, Hieter P, Sidransky D. A putative oncogenic role for MPPI1 in head and neck squamous cell cancer. Cancer Res 2000;60:5529-35.
45. Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack IF, Poque-Geile K, Lotze MT, Bozik ME, Chambers WH. Immunization with an antigen identified by cytokine tumor vaccina-assisted SEREX (CAS) suppressed growth of the rat9L glioma in vivo. Cancer Res 2001;61:2625-31.
46. Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 2000;60:2449-57.
47. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM, Vissers DC, ten Bosch GJ, Kester MG, Sijts A, Wouter Drijfhout J, Ossendorp F, et al. Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
48. Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: key players in growth, differentation, migration and tumor progression. Curr Opin Cell Biol 1994;6:726-33.
49. Hall CL, Yang B, Yang X, Zhang S, Turley M, Samuel S, Lange LA, Wang C, Curpen GD, Savani RC. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell 1995;82:19-26.
50. Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood 1999;93:1684-96.
51. Wang C, Thor AD, Moore II DH, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with over-expression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Can Res 1998;4:567-76.